HHS Orders FDA To Ease Enforcement On Certain Unapproved Peptide Drugs
On Wednesday, October 28, 2026, the Department of Health and Human Services directed the FDA to allow enforcement discretion for six unapproved peptide drugs.[1]
The policy lets small 503A compounding pharmacies make limited supplies of the peptides while explicitly excluding larger 503B outsourcing facilities.[1]
It covers six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.[1] They are commonly promoted for ulcerative colitis, insomnia, wound healing, metabolic health and migraine despite limited clinical evidence.[1] Florida-based compounder Olympia and Wesley Pharmaceuticals said its 503A facility will likely compound only one peptide at first and cannot meet expected national demand.[1] Alliance for Pharmacy Compounding CEO Scott Brunner said the decision offers a more accountable alternative to gray-market peptides but warned that suppliers and pharmacies must verify compliance, so dispensing could take time.[1]
A July 2026 FDA advisory panel voted to broaden access to the six peptides through compounding pharmacies.[1] But AP reporting, carried by PBS, says FDA scientists opposed the Trump administration's move to ease access to the drugs.[2]
Show source details & analysis (2 sources)
📌 Key Facts
- On Wednesday, October 28, 2026, NPR reported additional operational details of the HHS policy allowing enforcement discretion for six peptides, focusing on how it will work for small 503A compounding pharmacies.
- The policy explicitly excludes larger 503B outsourcing facilities, meaning only 503A compounding pharmacies can make the six peptides and only in relatively small quantities.
- NPR reiterates the six peptides and associates them with common but unproven uses: BPC-157 (ulcerative colitis), Epitalon (insomnia), KPV (wound healing), MOTS-c (metabolic health), Semax (migraine), and TB-500 (wound healing).
- The report notes a July 2026 FDA advisory panel voted in favor of expanded access to these peptides via compounding pharmacies even as FDA staff scientists opposed easing restrictions.
- Florida-based compounder Olympia and Wesley Pharmaceuticals said it will likely compound only one of the six peptides initially and that its 503A facility will not be able to meet expected national demand.
- Alliance for Pharmacy Compounding CEO Scott Brunner said the group is pleased because the move offers a more accountable alternative to gray-market peptides and brings patients into systems with pharmacy standards, oversight, and adverse-event reporting, but cautioned that ingredient suppliers and pharmacies must verify compliance and that it may take time before dispensing begins.
📰 Source Timeline (2)
Follow how coverage of this story developed over time
- On Wednesday, October 28, 2026, NPR reported additional operational details of the HHS policy allowing enforcement discretion for six peptides, focusing on how it will work for small 503A compounding pharmacies.
- The policy explicitly excludes larger 503B outsourcing facilities, meaning only 503A compounders can make the six peptides and only in relatively small quantities.
- Florida-based compounder Olympia and Wesley Pharmaceuticals said it will likely compound only one of the six peptides initially and that its 503A facility will not be able to meet expected national demand.
- Alliance for Pharmacy Compounding CEO Scott Brunner said the group is pleased with the decision because it offers a more accountable alternative to gray-market peptides and brings patients into systems with pharmacy standards, oversight, and adverse-event reporting.
- Brunner cautioned that it may take time for pharmacies to begin dispensing these peptides because ingredient suppliers must ensure their products meet policy requirements and pharmacies must verify compliance.
- The article reiterates the six peptides and associates them with common but unproven uses: BPC-157 (ulcerative colitis), Epitalon (insomnia), KPV (wound healing), MOTS-c (metabolic health), Semax (migraine), and TB-500 (wound healing).
- The NPR piece notes that a July 2026 FDA advisory panel voted in favor of expanded access to these peptides via compounding pharmacies even as FDA staff scientists opposed easing restrictions.